Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
14 evidence topics · 8 sources
Summary
The 2026 international guideline sequences treatment as a standard-dose second-generation H1-antihistamine first line, updosing up to 4-fold second line, then add-on omalizumab (recommended), dupilumab, or remibrutinib (both suggested) for CSU unresponsive to high-dose antihistamines, and off-label ciclosporin for CU unresponsive to licensed treatments. The guideline states that remibrutinib can be considered especially in patients who do not respond to both high-dose antihistamines and omalizumab, acknowledges cost restrictions on the three advanced therapies, and notes that treatments under development aim, among other approaches, to reduce mast cell numbers. A US Joint Task Force guideline that addresses the sequencing of conventional and advanced therapies was in draft for member review in 2026; the network meta-analysis commissioned for it rated standard-dose omalizumab (300 mg every 4 weeks) and remibrutinib among the most effective with high certainty. In a primary care pathway, patients who remain symptomatic and adherent after up to four times the standard antihistamine dose should be referred for specialist evaluation, where total IgE and IgG-anti-TPO may be tested to indicate the likelihood of response to omalizumab. The barzolvolimab phase 3 trials, which study adults with CSU who remain symptomatic despite H1 antihistamine treatment, enrolled 1,939 participants, including advanced therapy-experienced or refractory participants, and are designed to detect a difference in an omalizumab-refractory subpopulation. The manufacturer describes barzolvolimab as positioned “as a first-line therapy for patients with severe CSU or angioedema, and as the second-line advanced therapy of choice.” It is supplied for the trials in 1 mL pre-filled syringes for subcutaneous injection, which the manufacturer states allows potential self-administration at home.
International guideline update: development method
“This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proposed population: adults symptomatic despite H1 antihistamine treatment
Manufacturer positioning: first-line therapy in severe disease or angioedema and second-line advanced therapy
Enrollment of advanced therapy-experienced participants and design for an omalizumab-refractory subpopulation
Care setting: subcutaneous pre-filled syringe with potential self-administration at home
International guideline treatment algorithm: antihistamines, then omalizumab, dupilumab, or remibrutinib, then ciclosporin
“We recommend a 2nd generation H1-antihistamine as first-line treatment for all types of urticaria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend updosing of a 2nd generation H1-antihistamine up to 4-fold in patients with chronic urticaria unresponsive to a standard-dosed 2nd generation H1-antihistamines as second-line treatment before other treatments are considered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend adding on omalizumab* for the treatment of patients with CU unresponsive to high doses of 2nd generation H1-antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest using dupilumab* as add-on treatment for patients with CSU unresponsive to high doses of 2nd generation H1-antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest using remibrutinib* as add-on treatment for patients with CSU unresponsive to high doses of 2nd generation H1-antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest using ciclosporin* for the treatment of patients with CU unresponsive to licensed treatments or if these are not available.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
International guideline: positioning of remibrutinib and ciclosporin after omalizumab
“The use of remibrutinib can be considered in all patients with CSU and especially in patients who do not respond to both high-dose antihistamine and omalizumab treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ciclosporin is off-label for urticaria and is recommended only for patients with severe disease refractory to any other licensed treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
International guideline: cost and safety restrictions on advanced therapies
“It is strongly recommended to stick to the treatment algorithm, but it is acknowledged that omalizumab, dupilumab, and remibrutinib have restrictions due to their high cost, and that ciclosporin restricted due to its safety profile.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
International guideline: treatments under development that reduce mast cell numbers
Specialist care: biomarker testing and referral for comorbidities
“In patients under specialist care, additional tests, such as total IgE and IgG-anti-TPO may be performed, as they indicate the likelihood of response to omalizumab” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, any findings from the patient's medical history, physical examination, or basic testing that suggest the presence of a comorbidity or consequence of CSU should prompt further investigations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These may include screening for specific diseases by questionnaires, provocation tests, further laboratory tests, or a referral to a specialist.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary care pathway: specialist referral after up to fourfold antihistamine dosing
“Urticaria is a common condition presenting both as acute and chronic disease within primary care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If symptoms are controlled on any dose of a long-acting non-sedating antihistamine up to a maximum of four times the standard dose or if the symptoms have spontaneously remitted, no referral is necessary.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The corollary of this is that all patients who remain symptomatic and who have been adherent to medication, should be referred for specialist evaluation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote